IWHM6 | Biocytogen to Present 12 Posters on Innovative Mouse and Rat Models
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will attend the 6th International Workshop on Humanized Mice (IWHM6) held in Kyoto University, Japan, from October…
Read more
Biocytogen to Present at BioJapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress
Biocytogen will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce: Five RenMiceTM-based fully human…
Read more
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy
Beijing and Guangzhou, China, September 15, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co.,…
Read more
Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs
Beijing, China, September 1, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the company’s official listing on the Main Board of the…
Read more
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Beijing, China and San Diego, CA, August 29, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced…
Read more
Biocytogen Expands Partnership with Merck
Beijing, China and Darmstadt, Germany, August 25, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered into a global licensing agreement with Merck for the…
Read more
Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs
Beijing, China and Tokyo, Japan, July 21, 2022 – February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co.,…
Read more
Biocytogen/Eucure Biopharma Announce First Patient Dosed in Phase II Clinical Trial of YH003 Combination Therapy as a First-Line Treatment for Mucosal Melanoma
Beijing, China, July 12, 2022 -- Biocytogen subsidiary Eucure Biopharma announced that the first patient has been dosed in a phase II clinical trial (No.…
Read more
Biocytogen Europe Innovation Center Team to Present at AET-EU 2022, Introducing Project Integrum, TCR-mimic Platform and YH012
Beijing and Heidelberg, June 3, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") today announced 3 poster presentations for two novel fully human antibody platforms…
Read more
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Beijing, China, May 24, 2022 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will…
Read more